Acute Myeloid Leukemia | Disease Landscape & Forecast | G7 | 2022

Acute myeloid leukemia (AML) is the most common form of leukemia in adults and has historically been associated with poor five-year overall survival rates. In recent years, the AML treatment armamentarium has expanded with the regulatory approval of several targeted agents and drug reformulations. These new therapies have diversified the treatment paradigm from chemotherapy-based approaches to safer and more-effective targeted or personalized therapies. The approval of Bristol Myers Squibb’s Onureg has paved the way for drug development in the commercially lucrative maintenance setting. In addition, the early- and late-phase AML pipeline is active and spans several drug classes, including novel CD47-targeting agents, E-selectin inhibitors, vaccines, kinase inhibitors, small molecules, novel antibody technologies, and CAR T-cell therapies. With the uptake of new therapies and label expansions, we expect the AML market to grow substantially over the 10-year forecast period.

Questions answered:

  • What uptake and patient share can Onureg expect to capture as maintenance treatment in AML, and what competition will it face?
  • How will Roche / AbbVie’s Venclexta/Venclyxto perform in the highly lucrative newly diagnosed patient population ineligible for intensive treatment? Will its prescribing expand beyond this population?
  • How will second-generation FLT3 inhibitors (Astellas’s Xospata, Daiichi Sankyo’s Vanflyta) vie for a share of the FLT3-mutation-positive market?
  • Which emerging therapies are the most promising in AML? Which therapies could help address the unmet need for better treatments for TP53-mutated patients?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Geographies: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed incidence cases of AML by country, clinically, and market-relevant drug-treatable populations.

Forecast: 10-year, annualized, drug- and regimen-level sales and patient share of key AML therapies through 2031, segmented by brands / generics / biosimilars and drug-treatable subpopulations.

Emerging therapies: Phase III: 9 drugs; coverage of selected Phase II and Phase I products.

Login to access report